US drug maker to launch own brand of Covid-19 experimental drug in the country next month. Gilead has licensed the drug to four companies — Cipla, Mylan, Hetero and Jubilant Life Sciences — for sale in India, but none of these firms has received approval from the drug controller. most of the four companies are ready with their products and are awaiting nod from the regulator to manufacture and start selling the drug in the country.from Industry-Economic Times
Read The Rest:economictimes...